US83086J2006
© BusinessWire
26.11.2025
SKYE
LISTED
NASDAQ
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SKYE
News Preview
The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of SKYE during the c...
Themefolio
Profiler
Peergroup
© Newsfile
24.11.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Participate in Upcoming Investment Conferences
News Preview
San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences:Citi Global Healthcare Conference (Miami...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2025
SKYE
LISTED
NASDAQ
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit With the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Inv...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
18.11.2025
SKYE
LISTED
NASDAQ
Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”). Skye is a clinical stage biopharmaceutical company.
For more information, submit a fo...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
05.11.2025
SKYE
LISTED
NASDAQ
Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain
News Preview
During 12-week post-treatment period, nimacimab plus semaglutide blunts weight regain compared to semaglutide alone in subset analysis During 12-week post-treatment period, nimacimab plus semaglutide blunts weight regain compared to semaglutide alone in subset analysis...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
SKYE
LISTED
NASDAQ
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
News Preview
Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerability Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerability...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
News Preview
Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025 Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
News Preview
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 f...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions
News Preview
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it was selected to present new nimacimab data in its expanded preclinical model at the upcoming Amer...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Participate in Upcoming Investment Conferences
News Preview
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
SKYE
LISTED
NASDAQ
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
News Preview
Proprietary formulation technology being applied to potentially enhance properties of nimacimab Proprietary formulation technology being applied to potentially enhance properties of nimacimab...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.04.2025
SKYE
LISTED
NASDAQ
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on April 23, 2025, the Board of Directors granted a non-qualified stock option award to purchase 19,000 shares of its commo...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
14.04.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
News Preview
SAN DIEGO, April 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that its executive team will be available for 1x1 meetings at the Piper Sandler Spring Biopharma Sym...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
SKYE
LISTED
NASDAQ
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
News Preview
SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and fu...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.03.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
News Preview
SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, March 20th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2024 fourth quarter and...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
SKYE
LISTED
NASDAQ
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on February 24, 2025, the Board of Directors granted a non-qualified stock option award to purchase 56,000 shares of its com...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Participate in SXSW Session on Obesity
News Preview
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel ses...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
SKYE
LISTED
NASDAQ
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
News Preview
SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare conference on Thursday, January 16, 2025,...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
News Preview
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it has achieved more than 50% of targeted patient enrollment for its CBeyond™ Phase 2 clinical trial assessing nimacimab, a...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
News Preview
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the Board has appointed independent director Paul Grayson as Skye’s new Chairman of the Board, effective October 25, 2024. Mr. Gr...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2024
SKYE
LISTED
NASDAQ
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
News Preview
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2024
SKYE
LISTED
NASDAQ
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
News Preview
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.08.2024
SKYE
LISTED
NASDAQ
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on August 22, 2024, the Board of Directors granted a non-qualified stock option award to purchase 40,000 shares of its commo...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.08.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
News Preview
CBeyond™ will assess nimacimab’s ability to safely induce weight loss, and will also evaluate a combination of a GLP-1 receptor agonist plus nimacimab CBeyond™ will assess nimacimab’s ability to safely induce weight loss, and will also evaluate a combination of a GLP-1 receptor agonist plus nimacimab...
Themefolio
Profiler
Peergroup
© BusinessWire
16.08.2024
SKYE
LISTED
NASDAQ
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
News Preview
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SKYE....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.08.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
News Preview
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
08.08.2024
SKYE
LISTED
NASDAQ
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SKYE....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.07.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
News Preview
Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apnea Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apnea...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2024
SKYE
LISTED
NASDAQ
Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
News Preview
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will host a virtual KOL event entitled “Metabolic Rew...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
News Preview
Seasoned industry veteran adds significant global biotech and biopharma experience to Skye’s Board of Directors Seasoned industry veteran adds significant global biotech and biopharma experience to Skye’s Board of Directors...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
News Preview
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced the Company has been included in the Russell 2000® Index and...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
SKYE
LISTED
NASDAQ
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
News Preview
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will participate in the Piper Sa...
Themefolio
Profiler
Peergroup
© Newsfile
11.03.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Announces $40 Million Private Placement Equity Financing
News Preview
Financing expected to fund strategic expansion of obesity clinical development and extend operating runway beyond 2026San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) (the Company), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel classes of the...
Themefolio
Profiler
Peergroup
© Newsfile
07.02.2024
SKYE
LISTED
NASDAQ
Skye Bioscience to Present at Oppenheimer Investor Conference
News Preview
San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will present an overview of the company...
Themefolio
Profiler
Peergroup
© Newsfile
29.01.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
News Preview
Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 inhibitor, in combination with a GLP-1R agonistSan Diego, California--(Newsfile Corp. - January 29, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("the Company"), a clinical stage...
Themefolio
Profiler
Peergroup
© Newsfile
09.01.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
News Preview
Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity and chronic kidney diseaseSan Francisco, California--(Newsfile Corp. - January 9, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endo...
Themefolio
Profiler
Peergroup
© Newsfile
08.12.2023
SKYE
LISTED
NASDAQ
Skye Bioscience Responds to OTC Markets Promotional Policy
News Preview
San Diego, California--(Newsfile Corp. - December 8, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, focusing on metabolic conditions and glaucoma, has received a request by OTC Markets Group Inc. ("OTC Markets") to issue this statement about prom...
Themefolio
Profiler
Peergroup
© Newsfile
05.12.2023
SKYE
LISTED
NASDAQ
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
News Preview
San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system, and Tautomer Bioscience (Pty) Limited ("Tautomer"), a privately-owned biopharmaceutical company focused on addressing unmet medical...
Themefolio
Profiler
Peergroup
© Newsfile
21.11.2023
SKYE
LISTED
NASDAQ
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
News Preview
San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system to address diseases including glaucoma and metabolic conditions, will present an overview of its glaucoma program at two ophthalmology-focused conferences. Company...
Themefolio
Profiler
Peergroup
© Newsfile
25.10.2023
SKYE
LISTED
NASDAQ
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
News Preview
• SBI-100 OE is well tolerated, with low rate of hyperaemia (8.4%)• Reduced intraocular pressure (23% mean reduction) in healthy volunteers with higher baseline IOP (>17 mm Hg)San Diego, California--(Newsfile Corp. - October 25, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
